SCHEMBL9933771

SCHEMBL9933771

CCCCOC(=O)N1CCN(Cc2nn(C(=O)O)c3ccccc23)[C@@H](C)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
ELANE P08246 4/20 0.38
P2RY12 Q9H244 4/20 0.38
SMYD3 Q9H7B4 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
CHRM1 P11229 1/20 0.36
F2 P00734 1/20 0.35
PLAU P00749 1/20 0.35
HPGD P15428 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963106 0.78 CHRM2 (0.45) CHRM1
SCHEMBL9934812 0.72 KMT2A (0.46) P2RY12MEN1KMT2AF2ATM
SCHEMBL8503604 0.68 OPRD1 (0.48) OPRD1OPRK1L3MBTL1ADORA3HTR2A
SCHEMBL15882190 0.67 ELANE (0.56) EGFRELANEMEN1KMT2AF2
SCHEMBL4329419 0.67 PDK1 (0.56) OPRK1MEN1KMT2ACHRM1HTR2A
SCHEMBL7983086 0.67 PDK1 (0.55) OPRD1OPRK1HPGDATML3MBTL1
SCHEMBL7983089 0.67 PDK1 (0.55) OPRD1OPRK1HPGDATML3MBTL1
SCHEMBL7983083 0.67 PDK1 (0.55) OPRD1OPRK1HPGDATML3MBTL1
SCHEMBL2570900 0.66 POLB (0.51) P2RY12MEN1KMT2ACHRM1ATM
SCHEMBL22578805 0.66 POLB (0.46) SMYD3CHRM1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 EGFR 3708/4885OPRD1 10/4885OPRK1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.